15 August 2024
BerGenBio ASA: Registration of share capital reduction
Bergen, 15 August 2024: Reference is made to the stock exchange announcement made by BerGenBio ASA (the “Company”) on 23 May 2024 regarding the Company’s general meeting resolving a share capital decrease by reducing the nominal value of the Company’s shares by NOK 9 from NOK 10 to NOK 1, resulting in a decrease of the Company’s share capital by NOK 351,784,044, from NOK 390,871,160 to NOK 39,087,116.
The resolution was announced by the Norwegian Register of Business Enterprises on 28 May 2024, whereafter followed a six-week creditor notice period. The creditor period has been completed without objections.
The share capital reduction has now been registered with the Norwegian Register of Business Enterprises (Nw.: Foretaksregisteret). Following such registration the Company’s share capital is NOK 39,087,116 divided into 39,087,116 shares and voting rights, each share with a nominal value of NOK 1.
For further information, please contact:
Martin Olin, CEO, BerGenBio AS
ir@bergenbio.com
Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com
About BerGenBio ASA
BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including cancer and severe respiratory infections. The Company is focused on its proprietary lead candidate bemcentinib a potentially first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC and severe respiratory infections. BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The Company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more information, visit www.bergenbio.com.
This information is subject to the disclosure requirements pursuant to Section 5-8 and 5-12 of the Norwegian Securities Trading Act.
About Oncoinvent
Oncoinvent is developing Radspherin®, a receptor-independent alpha radiation therapy that leverages the unique anatomy of the abdominal cavity to destroy residual micrometastases using a single, highly localized dose of alpha radiation. The initial clinical focus is treatment of ovarian and colorectal cancer patients after surgical removal of the primary tumor and visible metastases in the peritoneum, the thin membrane lining the abdominal cavity and covering the abdominal organs.
This radiopharmaceutical is designed to prevent or delay recurrence in the peritoneal cavity, keeping patients disease-free for longer than the current standard of care and thereby also impacting overall survival. It is broadly applicable to any cancer that spreads to the peritoneum, e.g. ovarian, colorectal, and gastric cancers. Radspherin® stands out for its simplicity, excellent safety profile, and seamless integration into existing surgical workflows. Oncoinvent’s product is easy to use, avoids systemic delivery and significant toxicity. It is also differentiated in being simple to manufacture, scalable, and supply de-risked.
Data from two trials in ovarian (phase 1) and colorectal (phase 1/2a) cancers, are highly promising, showing an excellent safety profile and meaningful signals of efficacy. Interim data from an ongoing, randomized, controlled phase 2 ovarian cancer trial is expected in 2026. With cost-effective manufacturing, blockbuster potential, active pharma partnership momentum, plus strong endorsements from leading experts, Oncoinvent is built for scale and commercial success, and is set to become the new standard for post-surgical cancer care. The Company was founded by the originators of Algeta and Xofigo (acquired by Bayer).
